Aim To assess efficacy of omalizumab in moderate to severe asthma and notable factors affecting it, such as treatment compliance during the period of ten years. This retrospective, observational real life study is the first of this kind in the Gulf region and one of the worldwide rare long term omalizumab treatment studies. Methods The treatment for 35 patients started in 2008. Twenty patients (ongoing group) proceeded with treatment and were assessed annually until 2017. Reasons for treatment discontinuation in 15 patients (drop-out group) were also assessed. Results Before starting omalizumab the ongoing group of patients had history of ≥2 asthma exacerbations per year, which significantly decreased during the first year of the treatment (p<0.001), and for 14 (70%) patients ≤1 exacerbation stayed during the next 10 years. Since 2014 six (30%) patients had had ≥2 annual asthma exacerbations (p<0.05 in 2013; p<0.05 in 2014; p<0.001 in 2015; p<0.01 in 2016; p<0.001 in 2017). At the same time there was a significant drop in compliance index (CI) (p<0.0001). Conclusion To our knowledge this is the first 10-year study of compliance and effectiveness, which may help finalize some practical suggestions to improve CI in clinical practice and to note acceptable variation in CI. It is important to recognize factors that can possibly affect effectiveness of the treatment and identify the patients who will have the best benefit from a long term omalizumab treatment.
Braman S. The global burden of asthma. Chest. 2006.
2.
Rabe K, Adachi M, Lai C, Soriano J, Vermeire P, Weiss K, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. p. 40–7.
3.
Bush A, Zar H. WHO universal definition of severe asthma. Curr Opin Allergy Clin Immunol. 2011. p. 115–21.
4.
Khadadah M. The cost of asthma in Kuwait. Med Princ Pract. 2013. p. 87–91.
5.
Bateman E, Hurd S, Barnes P, Bousquet J, Drazen J, Fitzgerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008. p. 143–78.
6.
Global initiative for asthma. Global strategy for asthma management and prevention.
7.
Chung F, K. Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma. Expert Opin on Pharmacother. 2004. p. 439–46.
8.
Chipps B, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler S, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017. p. 1431–44.
9.
Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015. p. 8191.
10.
Snelder S, Weersink E, Braunstahl G. 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry. Allergy Asthma Clin Immunol. 2017. p. 34.
11.
Al-Ahmad M, Arifhodzic N, Nurkic J, Maher A, Rodriguez-Bouza T, Al-Ahmed N, et al. Real-life" efficacy and safety aspects of four-year omalizumab treatment for asthma. Medl Princ Pract. 2018. p. 260–6.
12.
Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggier P, Simonazzi A, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res. 2017. p. 368–72.
13.
Harjinder S, Peters J, Yogeet K, Diaz J. Impact of visit compliance on response to omalizumab therapy in a real-life clinical setting: reality study. J Allergy Clin Immunol. 2016.
14.
European medicines agency. 2AD.
15.
Suruki R, Daugherty J, Boudiaf N, Albers F. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017. p. 74.
16.
Nathan R, Sorkness C, Kosinski M, Schatz M, Li J, Marcus P, et al. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol. 2004. p. 59–65.
17.
Juniper E, Guyatt G, Epstein R, Ferrie P, Jaeschke R, Hiller T. Evaluation of impairment of health-related quality of life in asthma: Development of a questionnaire for use in clinical trials. Thorax. 1992. p. 76–83.
18.
Bousquet J, Rao S, Manga V. Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis. Eur Resp J. 2014. p. 3483.
19.
Schatz M, Kosinski M, Yarlas A, Hanlon J, Watson M, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009. p. 719–23.
20.
Lloyd A, Turk F, Leighton T, Canonica G. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ. 2007. p. 285–96.
21.
Guyatt G, Willan A, Griffith L. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994. p. 81–7.
22.
Tzortzaki E, Kampas G, Lemessios D, Markatos M, Adamidi M, Samara T, et al. Longterm omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012. p. 77–82.
23.
Zazzali J, Raimundo K, Trzaskoma B, Rosen K, Schatz M. Changes in asthma control, work productivity, and impairment with omalizumab:5 years EXCELS study results. Allergy Asthma Proc. 2015. p. 283–92.
24.
Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatic. J Asthma. 2011. p. 387–92.
25.
Caminati M, Senna G, Guerriero M, Dama A, Chieco-Bianchi F, Stefanizzi G, et al. Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address. Pulm Pharmacol Ther. 2015. p. 28–35.
26.
Holgate S. How to evaluate a patient’s response to anti-IgE. Eur Respir Rev. 2007. p. 78–84.
27.
Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe K, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011. p. 671–8.
28.
Walker S, Monteil M, Phelan K, Lasserson T, Walters E. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006.
29.
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005. p. 309–16.
30.
Brusselle G, Michils A, Louis R, Dupont L, Van De Maele B, Delobbe A, et al. Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009. p. 1633–42.
31.
Gouder C, West L, Montefort S. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm. 2015. p. 36–43.
32.
Hanania N, Alpan O, Hamilos D, Condemi J, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011. p. 573–82.
33.
Chen H, Eisner M, Haselkorn T, Trzaskoma. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med. 2013. p. 60–7.
34.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005. p. 487–97.
35.
Lindberg M, Ekstrom T, Moller M, Ahlner J. Asthma care and factors affecting medication compliance: the patient’s point of view. Int J Q Health Care. 2001. p. 375–83.
36.
Lafeuille M, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P. Association between consistent omalizumab treatment and asthma control. J Allergy Clin Immunol. 2013. p. 51–7.
37.
Janson S, Solari P, Trzaskoma B, Chen H, Haselkorn T, Zazzali J. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol. 2015. p. 516–21.
38.
Domingo C, Pomares X, Navarro A, Rudi N, Sogo A, Dávila I, et al. Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens: a pilot study. Int J Mol Sci. 2017. p. 521.
39.
Bilodeau L, Boulay M, Prince P, Boisvert P, Boulet L. Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology. 2010. p. 420–5.
40.
Yakinthou A, Tsavlis D, Megas I. The use of omalizumab in the treatment of nasal polyps. Chest. 2016.
41.
Gevaert P, Calus L, Van Zele T, Blomme K, Ruyck D, Bauters N, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013. p. 110–6.
42.
Samitas K, Delimpoura V, Zeroes E, Gaga M. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respire Rev. 2015. p. 594–601.
43.
Molimard M, Mala L, Bourdeix I, Gros L, V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014. p. 571–6.
44.
Busse W, Trazskoma B, Omachi T, Canvin J, Rosen K, Chipps B, et al. Evaluating omalizumab persistency of response after long-term therapy (XPORT). Eur Respir J. 2014. p. 3485.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
